2016
Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.Peer-Reviewed Original ResearchHigh-risk diseaseOncotype DXRisk diseaseChemotherapy costsODX testingBreast cancerAdjuvant chemotherapyRisk womenPatient outcomesEnd Results-Medicare dataEarly-stage breast cancerER-positive breast cancerReal-world clinical practiceIntermediate-risk womenSEER-Medicare populationLow-risk diseaseHigh-risk womenPositive breast cancerWorld clinical practiceActual patient outcomesTotal Medicare paymentsNCCN guidelinesOverall cohortMultivariable analysisPathologic features
2014
Intensity Modulated Radiation Therapy Utilization in the Treatment of Gastrointestinal Malignancies Between 2000 and 2009 in the SEER-Medicare Population
Palta M, Czito B, Willett C, Dinan M. Intensity Modulated Radiation Therapy Utilization in the Treatment of Gastrointestinal Malignancies Between 2000 and 2009 in the SEER-Medicare Population. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s401-s402. DOI: 10.1016/j.ijrobp.2014.05.1281.Peer-Reviewed Original ResearchSEER-Medicare populationRadiation therapy utilizationGastrointestinal malignanciesTherapy utilizationMalignancy